NF-kB inhibitor

About Eolo Pharma

Eolo Pharma is developing first-in-class oral thermogenic drugs that work by increasing resting energy expenditure, a novel mechanism distinct from current appetite-suppressing treatments. Its lead program, SANA/MVD-1, is positioned as a potential monotherapy or combination agent for obesity and its comorbidities, backed by peer-reviewed research published in journals like Nature Metabolism. The company is privately held, has a pipeline of 60 novel chemical entities, and is led by a team with expertise in metabolic science and drug development. Eolo's strategy targets the massive obesity market by offering a scientifically differentiated approach to reset metabolic health.

Therapeutic Areas

Other Alzheimer's Disease Drugs